Healthcare
Live Price
Offline$1.11
+11.00% today
1Y Change
+30.77%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vaccinex, Inc. (VCNX) is a Healthcare stock with listed on OTC. The stock last traded around $1.11 and up 30.8% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +5.4%, EPS growth of +79.7%, a dividend yield of 0.0%. What stands out right now is revenue +5.4%, EPS +79.7%, free cash flow +6.3% with operating margin -3117.3% and ROIC 760.7%. Valuation sits in the middle of the pack at price/sales 4.5. Stock Foundry combines VCNX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VCNX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VCNX Max Drawdown
-67.62%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VCNX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$50.0K
-94.4% YoY
FY Net Income
-$28.9M
-28.9% YoY
Free Cash Flow
-$28.9M
-14.2% YoY
Revenue Growth
+5.4%
EPS Growth
+79.7%
Gross Margin
100.0%
Net Margin
-3100.5%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 601K | 570K | 100K | 900K | 50K |
| Gross Profit | 601K | 570K | 68K | 731K | 48K |
| Operating Income | -19M | -23M | -20M | -22M | -28M |
| EBITDA | -19M | -20M | -20M | -21M | -28M |
| Net Income | -19M | -20M | -20M | -22M | -29M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1M | 2M | 6M | 9M | 11M |
| Total Assets | 3M | 4M | 8M | 10M | 12M |
| Total Liabilities | 5M | 6M | 3M | 2M | 14M |
| Shareholder Equity | -2M | -2M | 5M | 7M | -27M |
| Total Debt | 25K | 247K | 485K | 390K | 9M |
| Net Debt | -1M | -1M | -6M | -8M | -1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
29M
-13.2% YoY
Capital Expenditures
290K
-806.3% YoY
Free Cash Flow
29M
-14.2% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
-3117.3%
Net Margin
-3100.5%
ROE
776.6%
Debt / Equity
-0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.